ArticlePractical laboratory medicine2026
Adaptation of a routine immunoassay analyser for TSH measurement in dried blood spot and volumetric microsampling (Capitainer B50): evaluation for thyroid function testing in adults.
Article in Practical laboratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid-stimulating hormone (TSH) is the primary biomarker for diagnosing and monitoring thyroid disorders. Although serum remains the reference matrix, microsampling approaches, including dried blood spots (DBS) and volumetric devices (CPT B50), may improve accessibility and compliance. This study evaluated the analytical and clinical performance of TSH measurement from DBS and CPT B50 compared with serum. Methods: Paired serum, DBS, and CPT B50 samples were collected from 246 adults undergoing thyroid evaluation. DBS and CPT B50 samples were eluted and analyzed using a chemiluminescence immunoassay (RUO, LIAISON® XL, DiaSorin). Analytical performance, recovery, repeatability, stability, and method agreement were assessed. Microsample results were converted to serum-equivalent concentrations using inverse Passing-Bablok regression equations. Performance was evaluated using Passing-Bablok regression and Bland-Altman analysis with predefined acceptance criteria (bias ≤ ±15%, CV ≤ 15%, recovery 85%-115%), guided by CLSI EP15-A3 and EP17-A2 guidelines. Results: Repeatability CVs ranged from 3.7% to 10.4%, and recovery was 97%-110%. DBS and CPT B50 showed strong agreement with serum, with mean bias of -0.10 mIU/L for CPT B50 and 0.24 mIU/L for DBS. Samples remained stable for up to 8 weeks at +4 °C and -20 °C. Thyroid status classification accuracy was 96% for DBS and 98% for CPT B50. Conclusions: TSH measurement from DBS and CPT B50 showed high analytical and clinical concordance with serum. Volumetric sampling improved reproducibility and stability, supporting its use in remote thyroid testing and therapy monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.